UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 178

Sortiert nach

Bone marrow microenvironment and the identification of new targets for myeloma therapy

Leukemia, 2009-01, Vol.23 (1), p.10-24

2009

Volltextzugriff (PDF)

Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma

Current cancer drug targets, 2017-01, Vol.17 (9), p.782

2017

Volltextzugriff (PDF)

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

Blood, 2005-02, Vol.105 (4), p.1383-1395

2005

Volltextzugriff (PDF)

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

Leukemia, 2017-07, Vol.31 (7), p.1570-1581

2017

Volltextzugriff (PDF)

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

Leukemia, 2001-12, Vol.15 (12), p.1950-1961

2001

Volltextzugriff (PDF)

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

Cancer cell, 2005-11, Vol.8 (5), p.407-419

2005

Volltextzugriff (PDF)

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341

Blood, 2003-02, Vol.101 (4), p.1530-1534

2003

Volltextzugriff (PDF)

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application

British journal of haematology, 2005-01, Vol.128 (2), p.192-203

2005

Volltextzugriff (PDF)

A novel Bcl-2/Bcl-XL/Bcl-W inhibitor ABT-737 as therapy in multiple myeloma

Oncogene, 2007-04, Vol.26 (16), p.2374-2380

2007

Volltextzugriff (PDF)

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells

Leukemia, 2015-07, Vol.29 (7), p.1555-1563

2015

Volltextzugriff (PDF)

Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies

Current cancer drug targets, 2011-11, Vol.11 (9), p.1005

2011

Volltextzugriff (PDF)

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

Blood, 2004-12, Vol.104 (13), p.4188-4193

2004

Volltextzugriff (PDF)

A pivotal role for Mcl-1 in Bortezomib-induced apoptosis

Oncogene, 2008-01, Vol.27 (6), p.721-731

2008

Volltextzugriff (PDF)

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

Leukemia, 2009-05, Vol.23 (5), p.961-970

2009

Volltextzugriff (PDF)

Immunomodulatory analogs of thalidomide inhibit growth of Hs sultan cells and angiogenesis in vivo

Leukemia, 2003, Vol.17 (1), p.41-44

2003

Volltextzugriff (PDF)

Novel therapies targeting the myeloma cell and its bone marrow microenvironment

Seminars in oncology, 2001-12, Vol.28 (6), p.607-612

2001

Volltextzugriff (PDF)

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti–multiple myeloma (MM) activity and overcome bortezomib resistance

Blood, 2004-04, Vol.103 (8), p.3158-3166

2004

Volltextzugriff (PDF)

S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON‐ELIGIBLE PATIENTS WITH NDMM (AGMT‐MM02 TRIAL)

HemaSphere, 2022-06, Vol.6, p.80-81

2022

Volltextzugriff (PDF)

Cytokines and signal transduction

Best practice & research. Clinical haematology, 2005-01, Vol.18 (4), p.509-524

2005

Volltextzugriff (PDF)

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

The New England journal of medicine, 2019-08, Vol.381 (8), p.727-738

2019

Volltextzugriff (PDF)

P033 Mcl-1 confers protection of breast cancer cells exposed to hypoxia: therapeutic implications

Breast (Edinburgh), 2015-03, Vol.24, p.S37-S38

2015

Volltextzugriff (PDF)

The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e215-e215

2015

Volltextzugriff (PDF)

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

Cancer cell, 2009-10, Vol.16 (4), p.309-323

2009

Volltextzugriff (PDF)

Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway

Leukemia, 2007-03, Vol.21 (3), p.535-540

2007

Volltextzugriff (PDF)

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies

Pharmaceutics, 2018-10, Vol.10 (4), p.202

2018

Volltextzugriff (PDF)

1 – 25 von 178

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(172)
Mit Volltextzugriff
(161)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(120)
Life Sciences & Biomedicine
(106)
Humans
(87)
Biological And Medical Sciences
(57)
Medical Sciences
(43)
Multiple Myeloma - Pathology
(40)
Oncology
(38)
Multiple Myeloma - Drug Therapy
(34)
Hematology
(32)
Immunodeficiencies. Immunoglobulinopathies
(29)
Immunoglobulinopathies
(29)
Immunopathology
(29)
Apoptosis - Drug Effects
(26)
Multiple Myeloma
(26)
Cell Line, Tumor
(24)
Animals
(23)
Microbiology
(22)
Multiple Myeloma - Metabolism
(21)
Tumor Cells, Cultured
(21)
Antineoplastic Agents
(20)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bone marrow microenvironment and the identification of new targets for myeloma therapy

Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application

A novel Bcl-2/Bcl-XL/Bcl-W inhibitor ABT-737 as therapy in multiple myeloma

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells

Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

A pivotal role for Mcl-1 in Bortezomib-induced apoptosis

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

Immunomodulatory analogs of thalidomide inhibit growth of Hs sultan cells and angiogenesis in vivo

Novel therapies targeting the myeloma cell and its bone marrow microenvironment

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti–multiple myeloma (MM) activity and overcome bortezomib resistance

S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON‐ELIGIBLE PATIENTS WITH NDMM (AGMT‐MM02 TRIAL)

Cytokines and signal transduction

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

P033 Mcl-1 confers protection of breast cancer cells exposed to hypoxia: therapeutic implications

The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies

Suchergebnisse filtern